kif-18a-in-1

KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A. This compound demonstrates significant anti-tumor properties.

KIF18A-IN-13 (Compound 16) is an effective oral KIF18A inhibitor with in vivo anticancer properties. It can be utilized for the research of ovarian cancer.

KIF18A-IN-14 (Compound Example 81) is an inhibitor of KIF18A that exists in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit the viability of OVCAR-3 cells with IC50 values of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be utilized in tumor research, including studies on colon cancer, breast cancer, and lung cancer.

KIF18A-IN-15 (Compound Example 36) is a KIF18A inhibitor, available in two forms, EX36-A and its enantiomer EX36-B, both with an IC50 range of 0.01-0.1 μM. These compounds inhibit the viability of OVCAR-3 cells, with IC50 values of 0.01-0.1 μM for EX36-A and 0-0.01 μM for EX36-B. KIF18A-IN-15 is applicable in research on tumors, including colon, breast, and lung cancers.

KIF18A-IN-16 (Compound 15) is a polycyclic KIF18A inhibitor. It is applicable in research related to tumors, including colon cancer, breast cancer, and lung cancer.

KIF18A-IN-11 (Compound 13) is an effective inhibitor of KIF18A, exhibiting IC50 values below 100 nM in OVCAR3 and MDA-MB-157 cells. It is applicable for cancer research.

KIF18A-IN-17 (Example 37A) is a racemic form of a KIF18A inhibitor. It is applicable in research studies related to cancers such as breast and ovarian cancer.

KIF18A-IN-18 (Compound I) serves as an inhibitor of KIF18A and is applicable in studies of tumors characterized by chromosomal instability.

KIF18A-IN-19 (Compound 1) is an orally active inhibitor of KIF18A, with an IC50 of less than 0.1 μM. It exhibits anticancer properties against ovarian cancer.

KIF18A-IN-12 (compound 9), a potent KIF18A inhibitor, exhibits an IC 50 of 45.54 nM and is utilized in cancer research.

KIF18A-IN-10 (Compound 24) is a potent inhibitor of KIF18A with an IC50 value of 3.8 nM. It exhibits anticancer activity with IC50 values below 100 nM in OVCAR3 and MDA-MB-157 cells.